Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BRCA2 mutation
i
Other names:
BRCA2, BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, Breast cancer 2, early onset
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
675
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Related tests:
FoundationOne® CDx (110)
BRACAnalysis CDx™ (28)
FoundationOne® Liquid CDx (20)
Myriad myChoice® CDx (19)
FoundationOne® CDx (110)
BRACAnalysis CDx™ (28)
FoundationOne® Liquid CDx (20)
Myriad myChoice® CDx (19)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
BRCA2 mutation
Pancreatic Cancer
BRCA2 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
BRCA2 mutation
Peritoneal Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
BRCA2 mutation
Fallopian Tube Cancer
BRCA2 mutation
Fallopian Tube Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
BRCA2 mutation
Peritoneal Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
BRCA2 mutation
Fallopian Tube Cancer
BRCA2 mutation
Fallopian Tube Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
BRCA2 mutation
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
BRCA2 mutation
Fallopian Tube Cancer
BRCA2 mutation
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
BRCA2 mutation
Fallopian Tube Cancer
BRCA2 mutation
Fallopian Tube Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
BRCA2 mutation
Peritoneal Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA2 mutation
Prostate Cancer
BRCA2 mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
BRCA2 mutation
HER2 Negative Breast Cancer
BRCA2 mutation
HER2 Negative Breast Cancer
talazoparib
Sensitive: A1 - Approval
talazoparib
Sensitive
:
A1
talazoparib
Sensitive: A1 - Approval
talazoparib
Sensitive
:
A1
BRCA2 mutation
HER2 Negative Breast Cancer
BRCA2 mutation
HER2 Negative Breast Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
BRCA2 mutation
Prostate Cancer
BRCA2 mutation
Prostate Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
BRCA2 mutation
Peritoneal Cancer
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
BRCA2 mutation
Fallopian Tube Cancer
BRCA2 mutation
Fallopian Tube Cancer
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
BRCA2 mutation
Prostate Cancer
BRCA2 mutation
Prostate Cancer
abiraterone/niraparib
Sensitive: A1 - Approval
abiraterone / niraparib
Sensitive
:
A1
abiraterone/niraparib
Sensitive: A1 - Approval
abiraterone / niraparib
Sensitive
:
A1
BRCA2 mutation
Prostate Cancer
BRCA2 mutation
Prostate Cancer
niraparib
Sensitive: A2 - Guideline
niraparib
Sensitive
:
A2
niraparib
Sensitive: A2 - Guideline
niraparib
Sensitive
:
A2
BRCA2 mutation
Breast Cancer
BRCA2 mutation
Breast Cancer
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
olaparib
Sensitive: A2 - Guideline
olaparib
Sensitive
:
A2
BRCA2 mutation
Pancreatic Adenocarcinoma
BRCA2 mutation
Pancreatic Adenocarcinoma
cisplatin + gemcitabine
Sensitive: A2 - Guideline
cisplatin + gemcitabine
Sensitive
:
A2
cisplatin + gemcitabine
Sensitive: A2 - Guideline
cisplatin + gemcitabine
Sensitive
:
A2
BRCA2 mutation
Ovarian Cancer
BRCA2 mutation
Ovarian Cancer
bevacizumab
Resistant: A2 - Guideline
bevacizumab
Resistant
:
A2
bevacizumab
Resistant: A2 - Guideline
bevacizumab
Resistant
:
A2
BRCA2 mutation
HER2 Negative Breast Cancer
BRCA2 mutation
HER2 Negative Breast Cancer
PARP inhibitor
Sensitive: A2 - Guideline
PARP inhibitor
Sensitive
:
A2
PARP inhibitor
Sensitive: A2 - Guideline
PARP inhibitor
Sensitive
:
A2
BRCA2 mutation
Breast Cancer
BRCA2 mutation
Breast Cancer
talazoparib
Sensitive: A2 - Guideline
talazoparib
Sensitive
:
A2
talazoparib
Sensitive: A2 - Guideline
talazoparib
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
BRCA2 mutation
Triple Negative Breast Cancer
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
BRCA2 mutation
Triple Negative Breast Cancer
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
carboplatin
Sensitive: A2 - Guideline
carboplatin
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
BRCA2 mutation
Triple Negative Breast Cancer
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
BRCA2 mutation
Triple Negative Breast Cancer
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
BRCA2 mutation
Triple Negative Breast Cancer
BRCA2 mutation
Triple Negative Breast Cancer
vinorelbine tartrate
Sensitive: A2 - Guideline
vinorelbine tartrate
Sensitive
:
A2
vinorelbine tartrate
Sensitive: A2 - Guideline
vinorelbine tartrate
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login